Dear Investor, Atomo partner raises $25m in pre-IPO funding Congratulations to our partner, Lumos, which has raised $25m in a pre-IPO funding round, ahead of a likely float on the ASX next year. The Company exclusively uses Atomo’s Pascal device for its rapid blood test called FebriDx, which can indicate if a person has a bacterial or viral infection within 10 minutes. Atomo Managing Director, John Kelly said: “We’re very pleased that Lumos has been able to secure this funding, helped in part by using our Pascal device for its key FebriDx test. We look forward to working with them as they look to sell and market the test in markets where they have clinical approval.” You can read more about Lumos in an article in The Australian Financial Review (subscriber only) here. Media on our expanded agreement with Access Bio Our Managing Director, John Kelly sat down with ****** to discuss our rapid antigen test deal with Access Bio. The deal gives Atomo the non-exclusive rights to Access’ COVID-19 rapid antigen test in Australia, New Zealand and India under an Atomo brand. It could be a potential game changer in the diagnosis of COVID-19 as it will enable screening for acute infection and exposure to the virus at the same time, with results delivered after 10 mins at the point of testing. Watch the interview here. Our expanded partnership with Access Bio was also featured in Biotech Dispatch and you can read the article here. We look forward to updating you on our progress again soon. Kind regards, Atomo Investor Relations